Stage 4 nsclc prognosis

Pro Research Analysisby

Searched over 200M research papers

Analyzed relevant papers

Prognosis of Stage 4 Non-Small Cell Lung Cancer (NSCLC)

Impact of Sex on Prognosis in Stage 4 NSCLC

Survival Rates by Sex

Research indicates that sex is a significant prognostic factor in stage 4 non-small cell lung cancer (NSCLC). Females generally have a better prognosis compared to males. A study analyzing clinical data from multiple sources found that the median overall survival (OS) time for females was 19 months, compared to 12 months for males . This difference is statistically significant, with females showing a lower risk of death (HR = 0.77; 95% CI: 0.68-0.87; P < 0.001) .

EGFR Mutation and Treatment Response

The presence of EGFR-sensitizing mutations further enhances the survival advantage for females. Females with these mutations had a median OS of 32 months, compared to 19 months for males with the same mutations . Additionally, females benefited more from EGFR inhibitors in terms of both progression-free survival (PFS) and OS, with a median PFS of 21 months for females versus 12 months for males (P < 0.001) .

Treatment Approaches and Long-Term Survival

Chemo-Radiotherapy Outcomes

While the primary focus is on stage 4 NSCLC, insights from stage III sub-groups treated with chemo-radiotherapy can provide valuable context. A study on patients with stage T4N0-1 and single station IIIA-N2 NSCLC treated with individualized isotoxic accelerated radiotherapy (INDAR) and chemotherapy showed promising results. The median OS for T4N0-1 patients was 34 months, with a 2-year survival rate of 55% and a 5-year survival rate of 25% . For stage IIIA-N2 patients, the median OS was 26 months, with 2- and 5-year survival rates of 53% and 24%, respectively .

Conclusion

In summary, sex is a crucial factor in the prognosis of stage 4 NSCLC, with females generally having better survival outcomes than males. The presence of EGFR-sensitizing mutations further improves prognosis, particularly for females. Additionally, while not directly related to stage 4, the use of individualized isotoxic accelerated radiotherapy (INDAR) in stage III sub-groups shows promising long-term survival outcomes, which may inform treatment strategies for advanced stages. Understanding these factors can help in tailoring more effective treatment plans and improving survival rates for stage 4 NSCLC patients.

Sources and full results

Most relevant research papers on this topic

Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation.

Stage IV non-small-cell lung cancer patients with EGFR-sensitizing mutations have a significantly better prognosis than males, and considering sexes separately in survival rate estimation can lead to better outcomes.

Meta-Analysis

2020·

23citations

·Miguel Barquín et al.

Cancer epidemiology·

DOI

Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR).

Chemo-radiation using INDAR shows promising survival results in patients with single-station stage IIIA-N2 or T4N0-1 NSCLC.

Meta-Analysis

2014·

33citations

·B. Reymen et al.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·

DOI

Stage IV non-small cell lung cancer among young individuals: Incidence, presentations, and survival outcomes of conventional therapies

Stage IV non-small cell lung cancer patients aged 45 years have better survival outcomes than older patients, but require more attention due to their young age and socioeconomic implications.

2022·

3citations

·Jing-Sheng Cai et al.

Frontiers in Oncology·

DOI

Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI).

High NLR, high PLR, low LMR, and low ALI at baseline and post-treatment are significantly associated with poor overall survival in stage IV non-small cell lung cancer patients, regardless of age.

2019·

347citations

·Hiren Mandaliya et al.

Translational lung cancer research·

DOI

Prognostic factors by histologic subtype in stage IV non-small cell lung cancer (NSCLC): A population-based survival analysis of data from the Surveillance, Epidemiology, and End Results (SEER) Program (1988-2003).

Stage IV NSCLC survival improved over time, with demographic factors varying by histologic subtype, but overall survival remains poor.

Rigorous Journal

2016·

1citation

·K. Cetin et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·

DOI

Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: a systematic review and meta-analysis.

Tumor-size and nodal size-related factors are prognostic for overall survival in stage III non-small cell lung cancer patients.

Meta-Analysis

2020·

39citations

·Myra van Laar et al.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·

DOI

Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group.

Performance status and comorbidities are the main predictors of overall survival in elderly advanced non-small cell lung cancer patients selected based on a comprehensive geriatric assessment.

Meta-Analysis

2017·

12citations

·H. Le Caer et al.

Journal of thoracic disease·

DOI

A Robust 8-Gene Prognostic Signature for Early-Stage Non-small Cell Lung Cancer

The 8-gene prognostic signature developed in this study effectively predicts early-stage NSCLC outcomes, aiding in patient classification and personalized treatment decisions.

2019·

74citations

·Ru-kun He et al.

Frontiers in Oncology·

DOI

Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation

A multiphase approach for evaluating potential prognostic immunohistochemistry markers in non-small cell lung cancer is recommended.

Literature Review

2006·

196citations

·Chang-Qi Zhu et al.

Journal of Clinical Pathology·

DOI

Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non–Small Cell Lung Cancer

The individualized immune signature effectively predicts overall survival in early-stage nonsquamous non-small cell lung cancer patients, aiding in targeted therapy planning.

Rigorous Journal

2017·

390citations

·Bailiang Li et al.

JAMA Oncology·

DOI

Try another search

How do we study and understand consciousness and perception?

what does back pain from heart attack feel like

ace inhibitors efferent arteriole

diet to lower cholesterol

illnesses and diseases of the respiratory system

what are the signs pancreatic cancer